title: Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.
abstract: Glioblastoma multiforme is the most aggressive type of primary brain tumor. Glioblastoma growth dynamics vary widely across patients, making it difficult to accurately gauge their response to treatment. We developed a model-based metric of therapy response called Days Gained that accounts for this heterogeneity. Here, we show in 63 newly diagnosed patients with glioblastoma that Days Gained scores from a simple glioblastoma growth model computed at the time of the first postradiotherapy MRI scan are prognostic for time to tumor recurrence and overall patient survival. After radiation treatment, Days Gained also distinguished patients with pseudoprogression from those with true progression. Because Days Gained scores can be easily computed with routinely available clinical imaging devices, this model offers immediate potential to be used in ongoing prospective studies.
authors: Department of Pathology, University of Washington, Seattle, WA 98195, USA. mneal@uw.edu
authors: Maxwell Lewis
authors: ML
authors: Neal
authors: Andrew D
authors: AD
authors: Trister
authors: Sunyoung
authors: S
authors: Ahn
authors: Anne
authors: A
authors: Baldock
authors: Carly A
authors: CA
authors: Bridge
authors: Laura
authors: L
authors: Guyman
authors: Jordan
authors: J
authors: Lange
authors: Rita
authors: R
authors: Sodt
authors: Tyler
authors: T
authors: Cloke
authors: Albert
authors: A
authors: Lai
authors: Timothy F
authors: TF
authors: Cloughesy
authors: Maciej M
authors: MM
authors: Mrugala
authors: Jason K
authors: JK
authors: Rockhill
authors: Russell C
authors: RC
authors: Rockne
authors: Kristin R
authors: KR
authors: Swanson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011379:Prognosis; D016016:Proportional Hazards Models
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Cancer. 2008 Jul 15;113(2):405-10
references: 18484594
references: J Math Biol. 2009 Apr;58(4-5):561-78
references: 18815786
references: J Clin Oncol. 1990 Jul;8(7):1277-80
references: 2358840
references: Neurosurgery. 2010 Nov;67(5):1319-27; discussion 1327-8
references: 20871424
references: AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85
references: 21393407
references: Med Decis Making. 1988 Jul-Sep;8(3):197-203
references: 3398748
references: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references: 20231676
references: Brief Bioinform. 2010 Jan;11(1):111-26
references: 19955236
references: Clin Oncol (R Coll Radiol). 2008 May;20(4):301-8
references: 18308523
references: Lancet. 1986 Feb 8;1(8476):307-10
references: 2868172
references: Cell Prolif. 2000 Oct;33(5):317-29
references: 11063134
references: Math Med Biol. 2012 Mar;29(1):31-48
references: 21562060
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: J Digit Imaging. 2004 Sep;17(3):205-16
references: 15534753
references: J Neuropathol Exp Neurol. 2007 Jan;66(1):1-9
references: 17204931
references: BMC Bioinformatics. 2011 Mar 17;12:77
references: 21414208
references: J Clin Oncol. 2002 Mar 1;20(5):1375-82
references: 11870182
references: Curr Treat Options Oncol. 2011 Sep;12(3):240-52
references: 21594589
references: Cancer Res. 2009 May 15;69(10):4502-9
references: 19366800
references: Ann Neurol. 2003 Apr;53(4):524-8
references: 12666121
references: Nat Methods. 2012 Jul;9(7):671-5
references: 22930834
references: Phys Med Biol. 2010 Jun 21;55(12):3271-85
references: 20484781
references: Cancer Res. 2009 Dec 1;69(23):9133-40
references: 19934335
references: Curr Opin Neurol. 2009 Dec;22(6):633-8
references: 19770760